Products

Sutykine 12.5 mg Capsule (Sunitinib) Comprehensive Product Profile: What is Sutykine 12.5mg? Sutykine 12.5 mg is a high-potency oral oncology medication containing the active pharmaceutical ingredient Sunitinib. It belongs to a specialized class of drugs known as Tyrosine Kinase Inhibitors (TKIs). Sutykine is a “multi-targeted“ therapy, designed to identify and interfere with specific molecular pathways that allow tumors to survive, grow, and spread throughout the body. The 12.5mg dosage is often essential for precise clinical titration, allowing oncologists to adjust the treatment regimen based on individual patient tolerance and the specific stage of the malignancy. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Used as a standard first-line treatment for advanced kidney cancer. Gastrointestinal Stromal Tumors (GIST): For patients with stomach or bowel tumors that have progressed or who are intolerant to previous therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant RCC Therapy: Used to reduce the risk of cancer returning following a nephrectomy in high-risk patients. Mechanism of Action: How Sutykine Works Kinase Inhibition: It blocks enzymes called Tyrosine Kinases found on the surface of cancer cells. These enzymes act as communication signals; by blocking them, Sutykine prevents the “growth“ command from reaching the cell nucleus, halting uncontrolled cell division. Anti-Angiogenesis Strategy: It targets the Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off these “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Metastasis Suppression: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues and prevent the spread to distant organs. Detailed Clinical Instructions & Administration Dosing Schedule: Sutykine is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the capsule whole with water. It can be taken with or without food. Integrity: Do not crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Management of Potential Side Effects Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Endocrine: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist for proper oncology drug disposal. Why Choose Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, Thailand, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We Export Impex Medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sutib 12.5mg Capsule (Sunitinib) Detailed Product Information: What is Sutib 12.5mg? Sutib 12.5mg is a high-potency oral oncology medication containing the active ingredient Sunitinib. It belongs to a sophisticated class of drugs known as Tyrosine Kinase Inhibitors (TKIs). Sutib is a “multi-targeted“ therapy, designed to identify and interfere with specific molecular pathways that cancer cells use to grow, divide, and spread throughout the body. The 12.5mg dosage is essential for precise clinical titration, allowing oncologists to tailor the treatment regimen based on individual patient tolerance and the specific stage of the malignancy. Primary Therapeutic Indications : Advanced Renal Cell Carcinoma (RCC): Used as a primary treatment for advanced kidney cancer. Gastrointestinal Stromal Tumors (GIST): For patients with stomach or bowel tumors that have progressed or who are intolerant to previous therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant RCC Therapy: Reduces the risk of cancer returning following a nephrectomy in high-risk patients. Mechanism of Action: How Sutib Works: Signal Inhibition: It blocks enzymes called Tyrosine Kinases found on the surface of cancer cells. These enzymes act as communication signals; by blocking them, Sutib prevents the “growth“ command from reaching the cell nucleus. Anti-Angiogenesis: Sutib inhibits the Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This prevents the tumor from growing new blood vessels. By cutting off these “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Clinical Instructions & Administration : Dosing Schedule: Sutib is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the capsule whole with water. It can be taken with or without food. Integrity: Do not crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Management of Potential Side Effects L: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Metabolic: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Requirements : Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Safety: Keep strictly out of reach of children. Handle with care; if a capsule breaks, avoid breathing in the powder or getting it on your skin. Disposal: Do not dispose of oncology medications in household wastewater. Consult your local pharmacist for proper hazardous waste disposal. Why Choose Ernest Impex? ✔ GMP Quality: We ensure all oncology products meet the highest international manufacturing standards. ✔ Global Strategic Logistics: Specialized handling for pharmaceutical shipments to the USA, UK, Australia, and Singapore. ✔ Bulk Supply Specialist: A reliable partner for hospital procurement, oncology centers, and wholesale distributors. ✔ Competitive Export Pricing: Access high-quality Indian pharmaceutical exports at cost-effective rates. ✔ Documentation Support: We provide full assistance with COA (Certificate of Analysis), invoices, and customs documentation. We Export Impex Medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Lenome 5mg Capsule (Lenalidomide) Comprehensive Product Profile: What is Lenome 5mg? Lenome 5 mg is a potent oral medication containing the active pharmaceutical ingredient Lenalidomide. It is classified as an Immunomodulatory Imide (IMiD) and is a cornerstone in modern hematology-oncology. Lenome is designed to treat specific types of blood cancers and bone marrow disorders by altering the immune system's response and directly interfering with the growth of malignant cells. Primary Therapeutic Indications : Multiple Myeloma (MM): Used in combination with dexamethasone for patients with multiple myeloma, often as a first-line treatment or for maintenance therapy after a stem cell transplant. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma & Marginal Zone Lymphoma: Used in combination with rituximab for previously treated patients. Mechanism of Action: How Lenome Works : Tumor Cell Apoptosis: It directly inhibits the growth of tumor cells by inducing “programmed cell death“ (apoptosis). Anti-Angiogenesis: Lenome prevents the formation of new blood vessels that tumors need to grow. By cutting off these “nutrient supply lines,“ it effectively starves the tumor. Immune Enhancement: It stimulates the body's T-cells and Natural Killer (NK) cells, empowering the immune system to identify and destroy cancer cells more efficiently. Cytokine Modulation: It alters the production of cytokines (chemical messengers), reducing pro-inflammatory signals that help cancer cells survive and proliferate. Detailed Clinical Instructions & Administration: Dosing Schedule: Lenome is typically taken in cycles (e.g., 21 days of treatment followed by a 7-day rest period). Strictly follow the specific cycle prescribed by your hematologist. Administration: Swallow the 5mg capsule whole with water. It can be taken with or without food, but try to take it at the same time every day. Integrity: Do not open, break, or chew the capsules. If the powder inside a capsule is touched, wash the area immediately with soap and water. Pregnancy Prevention: Because Lenalidomide can cause severe birth defects, patients must adhere to a strict Risk Evaluation and Mitigation Strategy (REMS) or equivalent safety program. Management of Potential Side Effects Hematological: Neutropenia (low white blood cells), Thrombocytopenia (low platelets), and Anemia. Regular blood counts are essential. Thromboembolism: Increased risk of blood clots in the veins (DVT) or lungs (PE). Oncologists often prescribe blood thinners as a precaution. Gastrointestinal: Diarrhea, constipation, nausea, and abdominal pain. Dermatological: Rashes or itching (pruritus). Systemic: Fatigue, fever, and muscle cramps. Storage and Handling Protocols : Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Hazardous Waste: Do not dispose of unused capsules in household wastewater. Return unused medication to your healthcare provider for proper biohazardous disposal. Why Choose Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We Export Impex Medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Lynide 5mg Capsule (Lenalidomide) Comprehensive Product Profile: What is Lynide 5mg? Lynide 5 mg is a potent oral medication containing the active ingredient Lenalidomide. It belongs to a specialized class of drugs known as Immunomodulatory Imides (IMiDs). Lynide is a cornerstone in modern hematology-oncology, designed to treat specific types of blood cancers and bone marrow disorders by altering the immune system's response and directly targeting malignant cells. Primary Therapeutic Indications Multiple Myeloma (MM): Used in combination with dexamethasone for patients with multiple myeloma, often as a first-line treatment or for maintenance therapy. Myelodysplastic Syndromes (MDS): Specifically indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Mantle Cell Lymphoma (MCL): Prescribed for patients whose disease has relapsed or progressed after at least two prior therapies. Follicular Lymphoma & Marginal Zone Lymphoma: Used in combination with rituximab for previously treated patients. Mechanism of Action: How Lynide Works Tumor Cell Apoptosis: It directly inhibits the growth of tumor cells by inducing “programmed cell death“ (apoptosis). Anti-Angiogenesis: Lynide prevents the formation of new blood vessels that tumors need to grow. By cutting off the “nutrient supply lines,“ it effectively starves the tumor. Immune Enhancement: It stimulates the body's T-cells and Natural Killer (NK) cells, empowering the immune system to identify and destroy cancer cells more efficiently. Cytokine Modulation: It alters the production of cytokines (chemical messengers), reducing pro-inflammatory signals that help cancer cells survive. Detailed Clinical Instructions & Administration Dosing Schedule: Lynide is typically taken in cycles (e.g., 21 days of treatment followed by a 7-day rest period). Strictly follow the specific cycle prescribed by your hematologist. Administration: Swallow the 5mg capsule whole with water. It can be taken with or without food, but try to take it at the same time every day. Integrity: Do not open, break, or chew the capsules. If the powder inside a capsule is touched, wash the area immediately with soap and water. Pregnancy Prevention: Because Lenalidomide can cause severe birth defects, patients must adhere to a strict Risk Evaluation and Mitigation Strategy (REMS) or equivalent safety program. Management of Potential Side Effects Hematological: Neutropenia (low white blood cells), Thrombocytopenia (low platelets), and Anemia. Regular blood counts are essential. Thromboembolism: Increased risk of blood clots in the veins (DVT) or lungs (PE). Oncologists often prescribe blood thinners as a precaution. Gastrointestinal: Diarrhea, constipation, nausea, and abdominal pain. Dermatological: Rashes or itching (pruritus). Systemic: Fatigue, fever, and muscle cramps. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Hazardous Waste: Do not dispose of unused capsules in household wastewater. Return unused medication to your healthcare provider for proper biohazardous disposal. Why Choose Ernest Impex? ✔ GMP Standards: We ensure all oncology products meet rigorous international manufacturing benchmarks. ✔ Global Logistics Expertise: Specialized handling for pharmaceutical shipments to the USA, UK, Thailand, and Singapore. ✔ B2B Bulk Specialization: A reliable partner for hospital procurement, oncology clinics, and wholesale distributors. ✔ Competitive Export Pricing: Access high-quality Indian pharmaceutical exports at cost-effective rates. ✔ Documentation Support: Full assistance with COA (Certificate of Analysis), invoices, and customs documentation. We Export Impex Medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sutekast 12.5 mg Capsule (Sunitinib) Detailed Product Information: What is Sutekast 12.5mg? Sutekast 12.5 mg is a high-potency oral oncology medication containing the active pharmaceutical ingredient Sunitinib. It is classified as a multikinase inhibitor (TKI) and represents a landmark shift in personalized cancer care. Unlike traditional chemotherapy that non-selectively attacks all rapidly dividing cells, Sutekast is designed to identify and interfere with specific molecular pathways that allow tumors to survive, grow, and spread. The 12.5mg dosage is often utilized for precise dose titration, allowing oncologists to adjust treatment based on patient tolerance and therapeutic response, ensuring a balanced approach to efficacy and safety. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Widely recognized as a standard therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Utilized for patients with stomach or bowel tumors that have progressed despite previous therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer recurrence following surgery in high-risk kidney cancer patients. Mechanism of Action: How Sutekast Works Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases found on the surface of cancer cells. These enzymes act as “on-switches“ for growth. By locking these switches in the “off“ position, Sutekast stops the signals that tell cancer cells to multiply. Anti-Angiogenesis Strategy: Sutekast targets Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off the “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Metastasis Suppression: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues and help prevent the spread to other organs. Detailed Clinical Instructions Dosing Schedule: Sutekast is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 12.5mg capsule whole with water. It can be taken with or without food. Integrity: Never crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration of the drug in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Management of Potential Side Effects Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Endocrine: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist for proper oncology drug disposal. Why Partner with Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, Thailand, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost-advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to the following: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sunixar 12.5mg Capsule (Sunitinib) Detailed Product Information: What is Sunixar 12.5mg? Sunixar 12.5 mg is an advanced oral oncology medication containing the active pharmaceutical ingredient Sunitinib. It belongs to a specialized class of drugs known as Tyrosine Kinase Inhibitors (TKIs). Sunixar is a “multi-targeted“ therapy, meaning it interferes with specific pathways that cancer cells use to grow, divide, and spread throughout the body. The 12.5mg dosage is often utilized for precise dose titration, allowing oncologists to adjust treatment based on patient tolerance and therapeutic response, ensuring a balanced approach to efficacy and safety. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): A primary treatment for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumor (GIST): Used for patients with stomach or bowel tumors that have progressed or for those who cannot tolerate other treatments. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Helps prevent the recurrence of kidney cancer in high-risk patients following surgical removal of the kidney. Mechanism of Action: How Sunixar Works Signal Inhibition: It blocks the Tyrosine Kinase enzymes found on the surface of cancer cells. These enzymes act as communication signals; by blocking them, Sunixar prevents the “growth“ command from reaching the cell nucleus, halting uncontrolled cell division. Anti-Angiogenesis: It targets VEGF (Vascular Endothelial Growth Factor) and PDGF (Platelet-Derived Growth Factor) receptors. This prevents the tumor from growing new blood vessels. By cutting off these “nutrient supply lines,“ the tumor is starved of oxygen and nutrients. Metastasis Suppression: By disrupting cellular signaling, it inhibits the ability of malignant cells to migrate from the primary site to other organs. Detailed Clinical Instructions To ensure the safety and efficacy of Sunitinib therapy, strictly follow these administration guidelines: Dosage: Always follow the exact dosage and cycle prescribed by your oncologist. The 12.5mg dose is often used for precise titration. Administration: Swallow the capsule whole with water. You may take it with or without food. Integrity: Do not crush, chew, or open the capsule, as this can affect drug absorption and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain steady blood levels. Cycle Management: Sunixar is frequently taken in cycles (e.g., 4 weeks on, 2 weeks off). Do not skip days unless instructed by a physician. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Potential Side Effects Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Skin discoloration (often a yellowish tint), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: High blood pressure (hypertension). Regular monitoring is essential. Systemic: Fatigue, weakness, and decreased appetite or altered taste (dysgeusia). Hematological: Potential for decreased white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Requirements Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Safety: Keep strictly out of reach of children and pets. Waste Management: Do not dispose of oncology medications in household wastewater. Consult your local pharmacist for proper hazardous waste disposal. Why Choose Ernest Impex? ✔ GMP Quality: We ensure all oncology products meet the highest international manufacturing standards. ✔ Worldwide Strategic Logistics: Expertise in shipping to USA, UK, Thailand, Australia, Singapore, and Jamaica. ✔ Bulk Supply Specialist: A reliable partner for hospital procurement, oncology centers, and wholesale distributors. ✔ Competitive Export Pricing: Access high-quality Indian pharmaceutical exports at cost-effective rates. ✔ Documentation Support: We provide full assistance with COA, invoices, and customs documentation for seamless delivery. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sunisam 12.5mg Capsule (Sunitinib) Detailed Product Information: What is Sunisam 12.5mg? Sunisam 12.5mg is an advanced oral oncology medication containing the active pharmaceutical ingredient Sunitinib. It belongs to a specialized class of drugs known as Tyrosine Kinase Inhibitors (TKIs). Sunisam is a “multi-targeted“ therapy, meaning it interferes with specific pathways that cancer cells use to grow, divide, and spread throughout the body. The 12.5mg dosage is often utilized for precise dose titration, allowing oncologists to adjust treatment based on patient tolerance and therapeutic response, ensuring a balanced approach to efficacy and safety. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): A primary treatment for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumor (GIST): Used for patients with stomach or bowel tumors that have progressed or for those who cannot tolerate other treatments. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Helps prevent the recurrence of kidney cancer in high-risk patients following surgical removal of the kidney. Mechanism of Action: How Sunisam Works Sunisam 12.5mg employs a multi-pronged approach to dismantle the biological infrastructure of a tumor: Signal Inhibition: It blocks the Tyrosine Kinase enzymes found on the surface of cancer cells. These enzymes act as communication signals; by blocking them, Sunisam prevents the “growth“ command from reaching the cell nucleus, halting uncontrolled cell division. Anti-Angiogenesis: It targets VEGF (Vascular Endothelial Growth Factor) and PDGF (Platelet-Derived Growth Factor) receptors. This prevents the tumor from growing new blood vessels. By cutting off these “nutrient supply lines,“ the tumor is starved of oxygen and nutrients. Metastasis Suppression: By disrupting cellular signaling, it inhibits the ability of malignant cells to migrate from the primary site to other organs. Detailed Clinical Instructions To ensure the safety and efficacy of Sunitinib therapy, strictly follow these administration guidelines: Dosage: Always follow the exact dosage and cycle prescribed by your oncologist. The 12.5mg dose is often used for precise titration. Administration: Swallow the capsule whole with water. You may take it with or without food. Integrity: Do not crush, chew, or open the capsule, as this can affect drug absorption and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain steady blood levels. Cycle Management: Sunisam is frequently taken in cycles (e.g., 4 weeks on, 2 weeks off). Do not skip days unless instructed by a physician. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Potential Side Effects Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Skin discoloration (often a yellowish tint), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: High blood pressure (hypertension). Regular monitoring is essential. Systemic: Fatigue, weakness, and decreased appetite or altered taste (dysgeusia). Hematological: Potential for decreased white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Requirements Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Safety: Keep strictly out of reach of children and pets. Waste Management: Do not dispose of oncology medications in household wastewater. Consult your local pharmacist for proper hazardous waste disposal. Why Choose Ernest Impex? ✔ GMP Quality: We ensure all oncology products meet the highest international manufacturing standards. ✔ Worldwide Strategic Logistics: Expertise in shipping to USA, UK, Thailand, Australia, Singapore, and Jamaica. ✔ Bulk Supply Specialist: A reliable partner for hospital procurement, oncology centers, and wholesale distributors. ✔ Competitive Export Pricing: Access high-quality Indian pharmaceutical exports at cost-effective rates. ✔ Documentation Support: We provide full assistance with COA, invoices, and customs documentation for seamless delivery. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sugistran 12.5mg Capsule (Sunitinib) Comprehensive Product Profile: What is Sugistran 12.5 mg Sugistran 12.5mg is a highly specialized oral oncology medication containing the active ingredient Sunitinib. It belongs to a class of drugs known as Multi-Kinase Inhibitors (TKIs). This 12.5mg strength is critical for precise dose titration, allowing oncologists to tailor treatment regimens to the specific needs and tolerance levels of the patient. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): A frontline treatment for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): For stomach or bowel tumors that have progressed or for patients who are intolerant to previous therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer recurrence in high-risk patients following a nephrectomy (kidney removal). Mechanism of Action: How Sugistran Works Sugistran 12.5mg utilizes a “multi-targeted“ pharmacological approach to disrupt the biological infrastructure of the tumor. Tyrosine Kinase Inhibition: It blocks specific enzymes called Tyrosine Kinases found on the surface of cancer cells. These enzymes act as “switches.“ By locking these switches in the “off“ position, Sugistran prevents the signals that tell cancer cells to multiply and grow. Anti-Angiogenesis Strategy: It targets Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off the “nutrient supply lines,“ the tumor is deprived of oxygen and essential nutrients, leading to shrinkage. Metastasis Suppression: By disrupting vital survival pathways, the medication helps slow or prevent the spread of malignant cells to other parts of the body. Detailed Clinical Instructions To ensure maximum therapeutic efficacy and patient safety, follow these administration guidelines: Dosing Schedule: Sugistran is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 12.5mg capsule whole with water. It can be taken with or without food. Integrity: Never crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration of the drug in your bloodstream. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Management of Potential Side Effects As a potent anti-cancer agent, Sugistran 12.5mg may cause adverse reactions. Early identification is key to effective management: Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Endocrine: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C. Child Safety: Keep strictly out of reach of children and pets. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist or healthcare provider for proper oncology drug disposal. Why Choose Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, Singapore, and Thailand. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Rcnet 12.5mg Capsule (Sunitinib) What is Rcnet 12.5 mg Capsule? Rcnet 12.5 mg is a high-potency oral medication containing Sunitinib, a breakthrough in the field of targeted cancer treatment. It belongs to the class of drugs known as multi-kinase inhibitors (TKIs). Rcnet 12.5 mg is often utilized for precise dose titration or as part of a combination regimen for patients battling complex malignancies. Key Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): A primary treatment for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Used for stomach or bowel tumors that have progressed or for patients who cannot tolerate other therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant RCC Treatment: Helps reduce the risk of cancer returning after surgery in high-risk patients. Mechanism of Action: How Rcnet Works Rcnet 12.5 mg operates through a sophisticated “multi-targeted“ pharmacological approach to disrupt cancer progression: Kinase Inhibition: It blocks specific enzymes called Tyrosine Kinases. These enzymes act as communication signals that tell cancer cells to grow and multiply. By blocking these receptors, Rcnet halts the uncontrolled division of malignant cells. Anti-Angiogenesis: It inhibits the Vascular Endothelial Growth Factor (VEGF) receptors. This prevents the tumor from developing its own blood vessels. Without a dedicated blood supply, the tumor is deprived of oxygen and nutrients, leading to tumor shrinkage. Metastasis Suppression: By disrupting cellular signaling, it helps prevent the spread of cancer cells from the primary site to distant organs. Detailed Instructions for Use To achieve the best therapeutic results and ensure safety, follow these clinical guidelines: Administration: Take the capsule orally with a full glass of water. It can be taken with or without food. Consistency: Take your dose at the same time every day to maintain steady blood concentrations. Handling: Swallow the capsule whole. Do not crush, chew, or open the capsule. The Cycle: Sunitinib is often administered in a specific cycle (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the schedule provided by your oncologist. Potential Side Effects As a potent anti-cancer agent, Rcnet may cause side effects that require careful monitoring: Common: Fatigue, diarrhea, nausea, vomiting, and a decreased appetite or altered sense of taste. Dermatological: Skin discoloration (often yellowing), dryness, or hand-foot syndrome (redness, swelling, or pain on the palms and soles). Cardiovascular: High blood pressure (hypertension) or changes in heart rhythm. Endocrine: Hypothyroidism (underactive thyroid), requiring periodic blood tests. Hematological: Potential decrease in white blood cell or platelet counts, which may increase infection or bruising risks. Storage and Handling Requirements Environment: Store in a cool, dry place away from direct sunlight and moisture. Temperature: Maintain storage at room temperature, ideally between 15°C to 30°C. Safety: Keep out of reach of children. Handle capsules with care; if a capsule breaks, avoid breathing in the powder or getting it on your skin. Why Choose Ernest Impex? ✔ GMP Quality Medicines: Every batch meets rigorous international manufacturing standards. ✔ Global Export Expertise: Specialized logistics for the USA, UK, UAE, Australia, and Singapore. ✔ Bulk Supply for Oncology Clinics: A reliable partner for hospital procurement and large-scale distribution. ✔ Competitive International Pricing: Providing affordable, high-quality Indian pharmaceutical exports. ✔ Secure Export Packaging: Specialized packaging ensures product integrity during international transit. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 https://wa.me/919359902383

Nitnib 12.5mg Capsule (Sunitinib) by Zydus Detailed Product Information: What is Nitnib 12.5mg? Nitnib 12.5mg, manufactured by Zydus, is an advanced oral oncology medication containing the active pharmaceutical ingredient Sunitinib. It belongs to a specialized class of drugs known as Tyrosine Kinase Inhibitors (TKIs). Nitnib is a “multi-targeted“ therapy, meaning it interferes with specific pathways that cancer cells use to grow, divide, and spread throughout the body. The 12.5mg dosage is often used for precise dose titration, allowing oncologists to adjust treatment based on patient tolerance and therapeutic response. Primary Therapeutic Indications Gastrointestinal Stromal Tumor (GIST): Used for patients with stomach or bowel tumors that have progressed or for those who cannot tolerate other treatments. Advanced Renal Cell Carcinoma (RCC): A primary treatment for advanced or metastatic kidney cancer. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Helps prevent the recurrence of kidney cancer in high-risk patients following surgery. Mechanism of Action: How Nitnib Works Nitnib 12.5 mg employs a multi-pronged approach to stop cancer progression: Signal Inhibition: It blocks the Tyrosine Kinase enzymes found on the surface of cancer cells. These enzymes act as communication signals; by blocking them, Nitnib prevents the “growth“ command from reaching the cell nucleus. Anti-Angiogenesis: It targets VEGF (Vascular Endothelial Growth Factor) receptors. This prevents the tumor from growing new blood vessels. By cutting off the blood supply, the tumor is starved of oxygen and nutrients. Metastasis Suppression: By disrupting cellular signaling, it inhibits the ability of malignant cells to migrate to other organs. Detailed Clinical Instructions To ensure the safety and efficacy of Sunitinib therapy, strictly follow these guidelines: Dosage: Always follow the exact dosage prescribed by your oncologist. The 12.5mg dose is often used for precise titration. Administration: Swallow the capsule whole with water. You may take it with or without food. Integrity: Do not crush, chew, or open the capsule. Consistency: Take your dose at the same time every day to maintain steady blood levels. Cycle Management: Nitnib is frequently taken in cycles (e.g., 4 weeks on, 2 weeks off). Do not skip days unless instructed by a physician. Potential Side Effects As a potent anti-cancer agent, Nitnib 12.5 mg can cause adverse reactions. Common side effects include: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Skin discoloration (yellowing of the skin), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: High blood pressure (hypertension). Regular monitoring is required. Systemic: Fatigue, weakness, and decreased appetite. Hematological: Potential for decreased blood cell counts (Anemia or Neutropenia). Storage and Handling Requirements Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Safety: Keep out of reach of children and pets. Handle with care; do not touch the powder if a capsule is accidentally broken. Why Choose Ernest Impex? ✔ GMP Quality: We ensure all oncology products, including Zydus Nitnib, meet the highest international manufacturing standards. ✔ Worldwide Strategic Logistics: Expertise in shipping to USA, UK, UAE, Australia, and Singapore. ✔ Bulk Supply Specialist: A reliable partner for hospital procurement, oncology centers, and wholesale distributors. ✔ Competitive Export Pricing: Access high-quality Indian pharmaceutical exports at cost-effective rates. ✔ Documentation Support: We provide full assistance with COA, invoices, and customs documentation for seamless delivery. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Mitant 12.5mg Capsule (Sunitinib) Detailed Product Information: What is Mitant 12.5 mg? Mitant 12.5 mg is an advanced oral oncology medication containing the active pharmaceutical ingredient Sunitinib. It belongs to a specialized class of drugs known as Tyrosine Kinase Inhibitors (TKIs). Mitant is a “multi-targeted“ therapy, meaning it interferes with specific pathways that cancer cells use to grow, divide, and spread throughout the body. The 12.5mg dosage is often used for precise dose titration, allowing oncologists to adjust treatment based on patient tolerance and therapeutic response. Primary Therapeutic Indications Gastrointestinal Stromal Tumor (GIST): Used for patients with stomach or bowel tumors that have progressed or for those who cannot tolerate other treatments. Advanced Renal Cell Carcinoma (RCC): A primary treatment for advanced or metastatic kidney cancer. Pancreatic Neuroendocrine Tumors (pNET): Specifically for progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Helps prevent the recurrence of kidney cancer in high-risk patients following surgery. Mechanism of Action: How Mitant Works Mitant 12.5 mg employs a multi-pronged approach to stop cancer progression: Signal Inhibition: It blocks the Tyrosine Kinase enzymes found on the surface of cancer cells. These enzymes act as communication signals; by blocking them, Mitant prevents the “growth“ command from reaching the cell nucleus. Anti-Angiogenesis: It targets VEGF (Vascular Endothelial Growth Factor) receptors. This prevents the tumor from growing new blood vessels. By cutting off the blood supply, the tumor is starved of oxygen and nutrients. Metastasis Suppression: By disrupting cellular signaling, it inhibits the ability of malignant cells to migrate to other organs. Detailed Clinical Instructions To ensure the safety and efficacy of Sunitinib therapy, strictly follow these guidelines: Dosage: The 12.5 mg dose is often used for precise titration or as part of a specific combination regimen. Always follow the exact dosage prescribed by your oncologist. Administration: Swallow the capsule whole with water. You may take it with or without food. Integrity: Do not crush, chew, or open the capsule. Consistency: Take your dose at the same time every day to maintain steady blood levels. Cycle Management: Mitant is frequently taken in cycles (e.g., 4 weeks on, 2 weeks off). Do not skip days unless instructed by a physician. Potential Side Effects As a potent anti-cancer agent, Mitant 12.5mg can cause adverse reactions. Common side effects include: Gastrointestinal: Nausea, diarrhea, vomiting, and mouth sores (stomatitis). Dermatological: Skin discoloration (yellowing of the skin), dryness, or hand-foot syndrome (painful redness and swelling on the palms and soles). Cardiovascular: High blood pressure (hypertension). Regular monitoring is required. Systemic: Fatigue, weakness, and decreased appetite. Hematological: Potential for decreased blood cell counts (Anemia or Neutropenia). Storage and Handling Requirements Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature: Maintain at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Safety: Keep out of reach of children and pets. Handle with care; do not touch the powder if a capsule is accidentally broken. Why Choose Ernest Impex? ✔ GMP Quality: We ensure all oncology products meet the highest international manufacturing standards. ✔ Worldwide Strategic Logistics: Expertise in shipping to USA, UK, UAE, Australia, and Singapore. ✔ Bulk Supply Specialist: A reliable partner for hospital procurement, oncology centers, and wholesale distributors. ✔ Competitive Export Pricing: Access high-quality Indian pharmaceutical exports at cost-effective rates. ✔ Documentation Support: We provide full assistance with COA, invoices, and customs documentation for seamless delivery. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383

Sutekast 50mg Capsule (Sunitinib) Comprehensive Product Profile: What is Sutekast 50mg? Sutekast 50mg is a high-potency oral oncology medication containing the active pharmaceutical ingredient Sunitinib. Classified as a multikinase inhibitor (TKI), it represents a landmark shift in personalized cancer care. Unlike traditional chemotherapy that attacks all rapidly dividing cells, Sutekast is designed to identify and interfere with specific molecular pathways that allow tumors to survive, grow, and spread. Primary Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): Widely recognized as a standard therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Utilized for patients with stomach or bowel tumors that have progressed despite previous therapies. Pancreatic Neuroendocrine Tumors (pNET): Treats progressive, well-differentiated tumors located in the pancreas. Adjuvant Treatment: Used to reduce the risk of cancer recurrence following surgery in high-risk kidney cancer patients. Mechanism of Action: How Sutekast Disrupts Cancer Sutekast 50mg operates through a sophisticated “multi-receptor“ blockade to dismantle the tumor's biological infrastructure. Tyrosine Kinase Inhibition: It blocks enzymes known as Tyrosine Kinases found on the surface of cancer cells. These enzymes act as “on-switches“ for growth. By locking these switches in the “off“ position, Sutekast stops the signals that tell cancer cells to multiply. Anti-Angiogenesis Strategy: Sutekast targets Vascular Endothelial Growth Factor (VEGF) and Platelet-Derived Growth Factor (PDGF) receptors. This inhibits the growth of new blood vessels. By cutting off the “nutrient supply lines,“ the tumor is starved of oxygen and essential nutrients. Apoptosis Induction: By disrupting vital survival pathways, the medication can trigger programmed cell death (apoptosis) in malignant tissues. Detailed Clinical Instructions To ensure maximum therapeutic efficacy and patient safety, follow these administration guidelines: Dosing Schedule: Sutekast is typically administered in cycles (e.g., 4 weeks of daily treatment followed by a 2-week rest period). Strictly adhere to the specific cycle prescribed by your oncologist. Administration: Swallow the 50mg capsule whole with water. It can be taken with or without food. Integrity: Never crush, chew, or open the capsule, as this can affect the absorption rate and increase the risk of side effects. Consistency: Take your dose at the same time every day to maintain a steady concentration of the drug in your system. Dietary Note: Avoid grapefruit and grapefruit juice, as they can significantly increase the levels of Sunitinib in your blood to unsafe levels. Management of Potential Side Effects Sutekast 50mg is a powerful medication and may cause adverse reactions. Early identification is key: Gastrointestinal: Nausea, diarrhea, vomiting, and “stomatitis“ (mouth sores). Dermatological: Yellowish skin discoloration (non-jaundice), dryness, or Hand-Foot Syndrome (painful redness and swelling on the palms and soles). Cardiovascular: Hypertension (high blood pressure) is common; regular monitoring is essential. Endocrine: Changes in thyroid function (Hypothyroidism) or altered taste (dysgeusia). Hematological: Potential decrease in white blood cell or platelet counts, requiring periodic blood monitoring. Storage and Handling Protocols Environmental Control: Store in a cool, dry place away from direct sunlight and humidity. Temperature Range: Maintain storage at controlled room temperature, ideally between 15°C to 30°C (59°F to 86°F). Child Safety: Keep strictly out of reach of children. Waste Management: Do not dispose of unused capsules in household wastewater. Consult your local pharmacist for proper oncology drug disposal. Why Choose Ernest Impex? ✔ GMP Standards: We supply only products that meet rigorous international manufacturing benchmarks. ✔ Global Strategic Logistics: Expert handling of pharmaceutical shipments to the USA, UK, UAE, Australia, and Singapore. ✔ B2B Bulk Specialization: We are a preferred partner for international oncology clinics, hospitals, and wholesale distributors. ✔ Competitive Export Pricing: Access the cost advantages of the Indian pharmaceutical market without compromising on quality. ✔ Comprehensive Documentation: Full support with COA (Certificate of Analysis), invoices, and customs documentation. We export Impex medicines to: USA • UK • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia 📞 Contact Ernest Impex – Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites www.ernestimpex.com www.ernestpharmaceuticals.com www.oncologuymediciensupplier.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Chat: https://wa.me/919359902383